Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
| العنوان: | Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients |
|---|---|
| المؤلفون: | Ernst Kubista, H. Samonigg, Angelika Reiner, Elisabeth Kucera, Michael Gnant, Martina Mittlböck, Michael Seifert, M. Fridrik, Raimund Jakesz, P. Speiser, H. Hausmaninger, L. Szabo, Robert Zeillinger |
| المصدر: | European Journal of Cancer. 35:398-405 |
| بيانات النشر: | Elsevier BV, 1999. |
| سنة النشر: | 1999 |
| مصطلحات موضوعية: | Oncology, Cancer Research, Univariate analysis, medicine.medical_specialty, Mutation, Mammary gland, Biology, medicine.disease, medicine.disease_cause, Metastasis, medicine.anatomical_structure, Breast cancer, Low-dose chemotherapy, Internal medicine, medicine, Cancer research, Lymph node, Survival analysis |
| الوصف: | The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and steroid receptor positive breast cancer patients. Two hundred and five tumour samples from a randomised clinical trial of 596 lymph node- and steroid receptor positive breast cancer patients were included. All patients had been randomly allocated to receive 20 mg of adjuvant tamoxifen (TAM) daily for 2 years or TAM plus one cycle of low-dose, short-term chemotherapy. For detection of p53 mutations we used in vitro amplification by polymerase chain reaction and consecutively performed temperature gradient gel electrophoresis (PCR-TGGE) and direct sequencing. We found p53 mutations in 42/205 (20%) cases: 16/42 (38%) p53 mutations occurred within the L2/L3 domains of the p53 gene, and 26/42 (62%) outside the L2/L3 domains. p53 mutation served as a statistically significant parameter in predicting disease-free survival in univariate (P = 0.02) and multivariate (P = 0.009) analysis. For overall survival, no significant differences were observed. Patients with tumours that had p53 mutations within the L2/L3 domains of the gene showed no significant difference to those with mutations outside the L2/L3 domains for disease-free survival. For overall survival, mutations in the L2/L3 domains showed a marginally significant difference (P = 0.05) in multivariate analysis, but not in univariate analysis (P = 0.13). We conclude that mutation in the L2/L3 domains of the p53 gene is not an independent prognostic indicator of disease outcome for patients suffering from breast cancer with lymph node metastases and positive steroid receptors. |
| تدمد: | 0959-8049 |
| DOI: | 10.1016/s0959-8049(98)00400-6 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::dfe9219779b8a16ad30805e352d25560 https://doi.org/10.1016/s0959-8049(98)00400-6 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi...........dfe9219779b8a16ad30805e352d25560 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi...........dfe9219779b8a16ad30805e352d25560 779 3 unknown 778.720947265625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........dfe9219779b8a16ad30805e352d25560&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_________::dfe9219779b8a16ad30805e352d25560# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ernst+Kubista%22">Ernst Kubista</searchLink><br /><searchLink fieldCode="AR" term="%22H%2E+Samonigg%22">H. Samonigg</searchLink><br /><searchLink fieldCode="AR" term="%22Angelika+Reiner%22">Angelika Reiner</searchLink><br /><searchLink fieldCode="AR" term="%22Elisabeth+Kucera%22">Elisabeth Kucera</searchLink><br /><searchLink fieldCode="AR" term="%22Michael+Gnant%22">Michael Gnant</searchLink><br /><searchLink fieldCode="AR" term="%22Martina+Mittlböck%22">Martina Mittlböck</searchLink><br /><searchLink fieldCode="AR" term="%22Michael+Seifert%22">Michael Seifert</searchLink><br /><searchLink fieldCode="AR" term="%22M%2E+Fridrik%22">M. Fridrik</searchLink><br /><searchLink fieldCode="AR" term="%22Raimund+Jakesz%22">Raimund Jakesz</searchLink><br /><searchLink fieldCode="AR" term="%22P%2E+Speiser%22">P. Speiser</searchLink><br /><searchLink fieldCode="AR" term="%22H%2E+Hausmaninger%22">H. Hausmaninger</searchLink><br /><searchLink fieldCode="AR" term="%22L%2E+Szabo%22">L. Szabo</searchLink><br /><searchLink fieldCode="AR" term="%22Robert+Zeillinger%22">Robert Zeillinger</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>European Journal of Cancer</i>. 35:398-405 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier BV, 1999. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 1999 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+Research%22">Cancer Research</searchLink><br /><searchLink fieldCode="DE" term="%22Univariate+analysis%22">Univariate analysis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Mutation%22">Mutation</searchLink><br /><searchLink fieldCode="DE" term="%22Mammary+gland%22">Mammary gland</searchLink><br /><searchLink fieldCode="DE" term="%22Biology%22">Biology</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%5Fcause%22">medicine.disease_cause</searchLink><br /><searchLink fieldCode="DE" term="%22Metastasis%22">Metastasis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Eanatomical%5Fstructure%22">medicine.anatomical_structure</searchLink><br /><searchLink fieldCode="DE" term="%22Breast+cancer%22">Breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Low-dose+chemotherapy%22">Low-dose chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+research%22">Cancer research</searchLink><br /><searchLink fieldCode="DE" term="%22Lymph+node%22">Lymph node</searchLink><br /><searchLink fieldCode="DE" term="%22Survival+analysis%22">Survival analysis</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and steroid receptor positive breast cancer patients. Two hundred and five tumour samples from a randomised clinical trial of 596 lymph node- and steroid receptor positive breast cancer patients were included. All patients had been randomly allocated to receive 20 mg of adjuvant tamoxifen (TAM) daily for 2 years or TAM plus one cycle of low-dose, short-term chemotherapy. For detection of p53 mutations we used in vitro amplification by polymerase chain reaction and consecutively performed temperature gradient gel electrophoresis (PCR-TGGE) and direct sequencing. We found p53 mutations in 42/205 (20%) cases: 16/42 (38%) p53 mutations occurred within the L2/L3 domains of the p53 gene, and 26/42 (62%) outside the L2/L3 domains. p53 mutation served as a statistically significant parameter in predicting disease-free survival in univariate (P = 0.02) and multivariate (P = 0.009) analysis. For overall survival, no significant differences were observed. Patients with tumours that had p53 mutations within the L2/L3 domains of the gene showed no significant difference to those with mutations outside the L2/L3 domains for disease-free survival. For overall survival, mutations in the L2/L3 domains showed a marginally significant difference (P = 0.05) in multivariate analysis, but not in univariate analysis (P = 0.13). We conclude that mutation in the L2/L3 domains of the p53 gene is not an independent prognostic indicator of disease outcome for patients suffering from breast cancer with lymph node metastases and positive steroid receptors. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 0959-8049 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/s0959-8049(98)00400-6 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_________::dfe9219779b8a16ad30805e352d25560" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_________::dfe9219779b8a16ad30805e352d25560</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1016/s0959-8049(98)00400-6" linkWindow="_blank">https://doi.org/10.1016/s0959-8049(98)00400-6</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi...........dfe9219779b8a16ad30805e352d25560 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/s0959-8049(98)00400-6
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 8
[StartPage] => 398
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[1] => Array
(
[SubjectFull] => Cancer Research
[Type] => general
)
[2] => Array
(
[SubjectFull] => Univariate analysis
[Type] => general
)
[3] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[4] => Array
(
[SubjectFull] => Mutation
[Type] => general
)
[5] => Array
(
[SubjectFull] => Mammary gland
[Type] => general
)
[6] => Array
(
[SubjectFull] => Biology
[Type] => general
)
[7] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[8] => Array
(
[SubjectFull] => medicine.disease_cause
[Type] => general
)
[9] => Array
(
[SubjectFull] => Metastasis
[Type] => general
)
[10] => Array
(
[SubjectFull] => medicine.anatomical_structure
[Type] => general
)
[11] => Array
(
[SubjectFull] => Breast cancer
[Type] => general
)
[12] => Array
(
[SubjectFull] => Low-dose chemotherapy
[Type] => general
)
[13] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[14] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[15] => Array
(
[SubjectFull] => Cancer research
[Type] => general
)
[16] => Array
(
[SubjectFull] => Lymph node
[Type] => general
)
[17] => Array
(
[SubjectFull] => Survival analysis
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ernst Kubista
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => H. Samonigg
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Angelika Reiner
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Elisabeth Kucera
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michael Gnant
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Martina Mittlböck
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michael Seifert
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => M. Fridrik
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Raimund Jakesz
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => P. Speiser
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => H. Hausmaninger
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => L. Szabo
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Robert Zeillinger
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 03
[Type] => published
[Y] => 1999
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 09598049
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 35
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => European Journal of Cancer
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |